Other OTC - Delayed Quote • USD
Malin Corporation plc (MLLNF)
At close: February 12 at 2:18 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. William F. Daniel | Executive Chairman of the Board | 133.78k | -- | 1952 |
| Ms. Fiona Dunlevy | Company Secretary & Executive Director | 293.26k | -- | 1983 |
| Andrea Stafford | Head of Finance | -- | -- | -- |
| Jessica Bergin | Director of Investor Relations & External Reporting | -- | -- | -- |
| Dr. Andrew C. von Eschenbach M.D. | Chief Medical Adviser | -- | -- | 1942 |
Malin Corporation plc
The Lennox Building
50 Richmond Street South
Dublin, D02 FK02
Ireland
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 3
Description
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It also provides company secretarial services and engages in investment activities. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.
Corporate Governance
Malin Corporation plc’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 9; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available